NASDAQ, TSX: NVCN
VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present
A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.
About Neovasc Inc.Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™ (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
View original content:http://www.prnewswire.com/news-releases/neovasc-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-300692129.html
SOURCE Neovasc Inc.
Subscribe to our Free Newsletters!